Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Motexafin gadolinium in the treatment of brain metastases.

Richards GM, Mehta MP.

Expert Opin Pharmacother. 2007 Feb;8(3):351-9. Review.

PMID:
17266469
2.

Motexafin gadolinium: a redox-active tumor selective agent for the treatment of cancer.

Evens AM.

Curr Opin Oncol. 2004 Nov;16(6):576-80. Review.

PMID:
15627019
3.

Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung cancer patients with brain metastases: results of a phase III trial.

Mehta MP, Shapiro WR, Phan SC, Gervais R, Carrie C, Chabot P, Patchell RA, Glantz MJ, Recht L, Langer C, Sur RK, Roa WH, Mahe MA, Fortin A, Nieder C, Meyers CA, Smith JA, Miller RA, Renschler MF.

Int J Radiat Oncol Biol Phys. 2009 Mar 15;73(4):1069-76. doi: 10.1016/j.ijrobp.2008.05.068. Epub 2008 Oct 30.

PMID:
18977094
4.

Lead-in phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases: centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points.

Mehta MP, Shapiro WR, Glantz MJ, Patchell RA, Weitzner MA, Meyers CA, Schultz CJ, Roa WH, Leibenhaut M, Ford J, Curran W, Phan S, Smith JA, Miller RA, Renschler MF.

J Clin Oncol. 2002 Aug 15;20(16):3445-53.

PMID:
12177105
5.
6.

Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases.

Mehta MP, Rodrigus P, Terhaard CH, Rao A, Suh J, Roa W, Souhami L, Bezjak A, Leibenhaut M, Komaki R, Schultz C, Timmerman R, Curran W, Smith J, Phan SC, Miller RA, Renschler MF.

J Clin Oncol. 2003 Jul 1;21(13):2529-36.

PMID:
12829672
7.

Motexafin gadolinium: a novel redox active drug for cancer therapy.

Magda D, Miller RA.

Semin Cancer Biol. 2006 Dec;16(6):466-76. Epub 2006 Sep 26. Review.

PMID:
17112739
8.
9.

Motexafin gadolinium: a novel radiosensitizer for brain tumors.

Francis D, Richards GM, Forouzannia A, Mehta MP, Khuntia D.

Expert Opin Pharmacother. 2009 Sep;10(13):2171-80. doi: 10.1517/14656560903179325.

PMID:
19640206
10.

Motexafin gadolinium: a novel radiosensitizer for brain tumors.

Forouzannia A, Richards GM, Khuntia D, Mehta MP.

Expert Rev Anticancer Ther. 2007 Jun;7(6):785-94. Review.

PMID:
17555388
11.

Evaluation of Motexafin gadolinium (MGd) as a contrast agent for intraoperative MRI.

Hirschberg H, Wu GN, Madsen SJ.

Minim Invasive Neurosurg. 2007 Dec;50(6):318-23. doi: 10.1055/s-2007-993158.

PMID:
18210352
12.

Motexafin gadolinium: a clinical review of a novel radioenhancer for brain tumors.

Khuntia D, Mehta M.

Expert Rev Anticancer Ther. 2004 Dec;4(6):981-9. Review.

PMID:
15606327
13.

Motexafin gadolinium: a possible new radiosensitiser.

Rodrigus P.

Expert Opin Investig Drugs. 2003 Jul;12(7):1205-10. Review.

PMID:
12831354
14.

Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial.

Meyers CA, Smith JA, Bezjak A, Mehta MP, Liebmann J, Illidge T, Kunkler I, Caudrelier JM, Eisenberg PD, Meerwaldt J, Siemers R, Carrie C, Gaspar LE, Curran W, Phan SC, Miller RA, Renschler MF.

J Clin Oncol. 2004 Jan 1;22(1):157-65.

15.

Therapeutic advances in the treatment of brain metastases.

Chang JE, Robins HI, Mehta MP.

Clin Adv Hematol Oncol. 2007 Jan;5(1):54-64. Review.

PMID:
17339829
16.

Current strategies in whole-brain radiation therapy for brain metastases.

Mehta MP, Khuntia D.

Neurosurgery. 2005 Nov;57(5 Suppl):S33-44; discusssion S1-4. Review.

PMID:
16237287
17.

4,5-Diethyl-10,23-dimethyl-9,24-bis(3-hydroxypropyl)-16,-17-bis(3,hydroxypropyl)oxy-13,20,25,26,27—pentaazapentacyclo-[20.2.1.13,6.19,11.014,19]heptacosa-3,5,8,10,12,14,16,18,20,22,24-undecaene gadolinium hydrates.

Zhang H.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2007 Dec 6 [updated 2008 Jan 08].

18.

Motexafin gadolinium induces oxidative stress and apoptosis in hematologic malignancies.

Evens AM, Balasubramanian L, Gordon LI.

Curr Treat Options Oncol. 2005 Jul;6(4):289-96. Review.

PMID:
15967082
19.

Noninvasive and nondestructive optical spectroscopic measurement of motexafin gadolinium in mouse tissues: comparison to high-performance liquid chromatography.

Kanick SC, Eiseman JL, Joseph E, Guo J, Parker RS.

J Photochem Photobiol B. 2007 Sep 25;88(2-3):90-104. Epub 2007 May 24.

PMID:
17604637
20.

Multicenter phase Ib/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases.

Carde P, Timmerman R, Mehta MP, Koprowski CD, Ford J, Tishler RB, Miles D, Miller RA, Renschler MF.

J Clin Oncol. 2001 Apr 1;19(7):2074-83.

PMID:
11283141
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk